Catheter Precision to Attend and Participate in the 46th Heart Rhythm Society
Catheter Precision (VTAK) announced its participation in the 46th annual Heart Rhythm Society (HRS) meeting from April 24-27, 2025, in San Diego. The conference will gather nearly 10,000 professionals in arrhythmia care and electrophysiology, featuring over 200 educational sessions and 3,400 scientific abstracts.
The company will present four research abstracts at HRS 2025: three for VIVO and one for LockeT. Key findings include:
- VIVO showed 94% accuracy in a 125 multi-center European study with 83% long-term procedural success
- Research demonstrating VIVO's effectiveness in mapping difficult-to-identify PVCs
- LockeT's safety and efficacy study in 139 patients for large-bore access procedures
- VIVO's 89% accuracy in predicting exit site locations for scar-dependent VT, with 86% of patients free from device therapy after one year
Catheter Precision (VTAK) ha annunciato la sua partecipazione al 46° congresso annuale della Heart Rhythm Society (HRS), che si terrà dal 24 al 27 aprile 2025 a San Diego. La conferenza riunirà quasi 10.000 professionisti nel campo delle aritmie e dell'elettrofisiologia, con oltre 200 sessioni formative e 3.400 abstract scientifici.
L'azienda presenterà quattro abstract di ricerca all'HRS 2025: tre relativi a VIVO e uno a LockeT. I risultati principali includono:
- VIVO ha mostrato una precisione del 94% in uno studio europeo multicentrico su 125 pazienti, con un successo procedurale a lungo termine dell'83%
- Ricerca che dimostra l'efficacia di VIVO nella mappatura di PVC difficili da identificare
- Studio sulla sicurezza ed efficacia di LockeT in 139 pazienti per procedure con accesso a grosso calibro
- VIVO ha raggiunto l'89% di accuratezza nel predire le sedi di uscita per VT dipendente da cicatrici, con l'86% dei pazienti liberi da terapia con dispositivi dopo un anno
Catheter Precision (VTAK) anunció su participación en la 46ª reunión anual de la Heart Rhythm Society (HRS), que se celebrará del 24 al 27 de abril de 2025 en San Diego. La conferencia reunirá a casi 10,000 profesionales en cuidado de arritmias y electrofisiología, con más de 200 sesiones educativas y 3,400 resúmenes científicos.
La empresa presentará cuatro resúmenes de investigación en HRS 2025: tres para VIVO y uno para LockeT. Los hallazgos clave incluyen:
- VIVO mostró un 94% de precisión en un estudio europeo multicéntrico con 125 pacientes y un éxito procedimental a largo plazo del 83%
- Investigación que demuestra la efectividad de VIVO en el mapeo de PVCs difíciles de identificar
- Estudio de seguridad y eficacia de LockeT en 139 pacientes para procedimientos con acceso de gran calibre
- VIVO alcanzó un 89% de precisión en la predicción de las ubicaciones de salida para VT dependiente de cicatrices, con el 86% de los pacientes libres de terapia con dispositivos después de un año
Catheter Precision (VTAK)는 2025년 4월 24일부터 27일까지 샌디에이고에서 열리는 제46회 연례 Heart Rhythm Society (HRS) 회의에 참여한다고 발표했습니다. 이 컨퍼런스에는 부정맥 치료 및 전기생리학 분야의 약 10,000명의 전문가가 모이며, 200개 이상의 교육 세션과 3,400개의 과학 초록이 발표됩니다.
회사는 HRS 2025에서 네 개의 연구 초록을 발표할 예정이며, 그 중 세 개는 VIVO, 하나는 LockeT 관련입니다. 주요 결과는 다음과 같습니다:
- VIVO는 125명의 다기관 유럽 연구에서 94%의 정확도를 보였으며, 장기 시술 성공률은 83%입니다
- 식별하기 어려운 PVC 매핑에 대한 VIVO의 효과를 입증한 연구
- 139명의 환자를 대상으로 한 대구경 접근 시술에서 LockeT의 안전성과 효능 연구
- VIVO는 흉터 의존성 VT의 출구 위치 예측에서 89%의 정확도를 기록했으며, 1년 후 86%의 환자가 장치 치료 없이 지냈습니다
Catheter Precision (VTAK) a annoncé sa participation au 46e congrès annuel de la Heart Rhythm Society (HRS) qui se tiendra du 24 au 27 avril 2025 à San Diego. La conférence rassemblera près de 10 000 professionnels spécialisés dans la prise en charge des arythmies et l’électrophysiologie, avec plus de 200 sessions éducatives et 3 400 résumés scientifiques.
L’entreprise présentera quatre résumés de recherche lors de HRS 2025 : trois pour VIVO et un pour LockeT. Les principales conclusions sont les suivantes :
- VIVO a démontré une précision de 94 % dans une étude européenne multicentrique de 125 patients, avec un taux de succès procédural à long terme de 83 %
- Recherche montrant l’efficacité de VIVO dans la cartographie des PVC difficiles à identifier
- Étude sur la sécurité et l’efficacité de LockeT chez 139 patients pour des procédures d’accès large calibre
- VIVO a atteint une précision de 89 % pour prédire les sites de sortie du VT dépendant des cicatrices, avec 86 % des patients sans thérapie par dispositif après un an
Catheter Precision (VTAK) gab seine Teilnahme an der 46. jährlichen Tagung der Heart Rhythm Society (HRS) vom 24. bis 27. April 2025 in San Diego bekannt. Die Konferenz wird fast 10.000 Fachleute aus dem Bereich der Arrhythmiebehandlung und Elektrophysiologie versammeln und über 200 Bildungssitzungen sowie 3.400 wissenschaftliche Abstracts bieten.
Das Unternehmen wird auf der HRS 2025 vier Forschungsabstracts präsentieren: drei zu VIVO und eines zu LockeT. Die wichtigsten Erkenntnisse sind:
- VIVO zeigte in einer multizentrischen europäischen Studie mit 125 Teilnehmern eine Genauigkeit von 94 % und eine langfristige Verfahrens-Erfolgsrate von 83 %
- Forschung, die die Wirksamkeit von VIVO bei der Kartierung schwer zu identifizierender PVCs belegt
- Sicherheits- und Wirksamkeitsstudie von LockeT bei 139 Patienten für Großkaliber-Zugangsverfahren
- VIVO erreichte eine Genauigkeit von 89 % bei der Vorhersage von Austrittsstellen bei narbenabhängigem VT, wobei 86 % der Patienten nach einem Jahr frei von Gerätetherapie waren
- None.
- None.
Fort Mill, S.C., April 24, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 46th annual Heart Rhythm Society (HRS) meeting. The HRS meeting will take place from April 24th to the 27th in San Diego, California.
HRS announced that the 46th conference will bring together nearly 10,000 scientists, allied professionals, and clinicians from the field of arrhythmia care and electrophysiology (EP) to showcase advancements in patient care. Attendees will experience the latest in research, innovation, and education in EP, including more than 200 educational sessions led by more than 2,000 expert faculty and abstract presenters worldwide. This year's meeting received over 3,400 scientific abstracts, a testament to the rapid growth and innovation in the field.
Four abstracts for Catheter Precision’s products (three for VIVO and one for LockeT) will be featured at HRS 2025.
- Friday, April 25, 2025 – Accuracy and Long-Term Outcomes from First Multi-Center Registry Experience for Non-Invasive Localization
- This data comes from a 125 multi-center study in Europe. The data demonstrates that VIVO was over
94% accurate, assisted physicians in determining workflow when used pre-procedure, and that the use of VIVO pre-procedure may improve long-term outcomes. Long-term procedural success was over83% .
- This data comes from a 125 multi-center study in Europe. The data demonstrates that VIVO was over
- Saturday, April 26, 2025 – Novel Three-Dimensional Mapping Integrating Electrocardiogram Morphology for Difficult-to-Map Premature Ventricular Contractions
- This study compiled data from two centers (Heart Hospital of New Mexico and Overland Park Regional Medical Center) and demonstrates how VIVO can improve mapping and ablation for PVCs that are otherwise difficult to map, identify and ablate.
- Saturday, April 26, 2025 – Efficacy and Safety of LockeT in Large-Bore Access Electrophysiological Procedures
- This data included 139 patients and demonstrated that LockeT is safe and effective for creating hemostasis in ablation procedures that utilize a large access site. The LockeT closure device is optimal for the large bore puncture sites like those found in procedures for the Boston Scientific Watchman device or the Medtronic Micra pacemaker.
- Sunday, April 27, 2025 – Diagnostic accuracy of a non-invasive mapping system for scar dependent VT exit site localisation: relationship to myocardial scar and successful ablation lesions
- This study is novel, and is the first study to demonstrate VIVO’s accuracy in scar dependent VT.
- VIVO predicted the exit site locations (
89% ) and had correlation (86% ) with the successful ablation sites. At one year follow-up86% of patients were free from any device therapy.
David Jenkins, CEO of Catheter Precision, said, “Having an abstract accepted at any conference is an accomplishment. Somewhere around
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA.
About VIVO
Catheter Precision's VIVO™ (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE mark.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
At the Company
David Jenkins
973-691-2000
info@catheterprecision.com
# # #
FAQ
What are the key findings from Catheter Precision's VIVO system presented at HRS 2025?
How many research abstracts will VTAK present at the 2025 Heart Rhythm Society meeting?
What are the clinical outcomes of the LockeT device study presented at HRS 2025?
What is the significance of VTAK's VIVO system in mapping difficult PVCs?
How many attendees and scientific abstracts will be featured at HRS 2025?
